Sign In
Buy CTXR
$0.570
-0.0620 (-9.81%)
At Close: Jul 31, 2026
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
08:31am, Tuesday, 02'nd Jan 2024
Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with CRB
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
08:30am, Tuesday, 02'nd Jan 2024
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceut
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
08:30am, Thursday, 09'th Nov 2023
CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critica
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transact
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
04:30pm, Monday, 18'th Sep 2023
CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerc
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
04:30pm, Wednesday, 06'th Sep 2023
CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerc
Citius Pharmaceuticals: Steer Clear From This One
06:55pm, Friday, 02'nd Jun 2023
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among inves
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
08:30am, Wednesday, 11'th Jan 2023
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
10:51am, Wednesday, 28'th Dec 2022
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
07:36am, Tuesday, 08'th Nov 2022
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
04:30pm, Thursday, 08'th Sep 2022
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Na
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
06:40pm, Tuesday, 05'th Jul 2022
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With th
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
09:30am, Wednesday, 18'th May 2022
CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-cl
3 Reddit Stocks to Buy in May
09:00am, Sunday, 08'th May 2022
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. M
